B37.7 R65.0 R65.1 B37.9
Conditions
Interventions
Group 1: Intervention group („BDG-guided group“): After obtaining the patients informed consent, and patient randomisation, BDG and mannan is determined from serum samples collected on day 1 and day 2
Sponsors
Uniklinik ErlangenMikrobiologisches Institut
Eligibility
Sex/Gender
All
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: The trial includes patients receiving antimycotic therapy (orally or i.v.) during the intensive care unit (ICU) stay, or during the 24 h preceding the transfer to the ICU without having been diagnosed with an invasive fungal infection.
Exclusion criteria
Exclusion criteria: 1. Proven invasive fungal infection 2. Age < 18 years 3. Pregnancy or breast-feeding person 4. Neutropenia/leukopenia 5. Prophylactic intake of antimycotics 6. BDG and mannan testing during the past 7 days 7. Moribund Patient 8. Participation in another intervention trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Use of antimycotic medication defined as daily doses applied untill day 28 | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. 28-days-mortality (safety endpoint) 2. Positivit of the BDG- and mannan-determination on day 3 3. Occurrence of proven invasive fungal infection 4. Duration of organ sustaining therapy (dialysis, invasive respiration, catecholamine Administration) 5. SOFA score determination in the ICU 6. Duration of the ICU stay 7. Duration of the inpatient stay 8. Occurrence of medication side effects 9. Proof of colonization with Candida spp. and antimycotic resistence testing 10. Cost of antimycotic treatment and BDG testing | — |
Countries
Germany
Contacts
Public ContactJürgen Held
Mikrobiologisches Institut
Outcome results
None listed